On Monday, Shares of AMETEK, Inc. (NYSE:AME), gained 0.45% to $53.29.
AMETEK, declared that it has accomplished the formerly declared acquisition of the Surface Inspection Systems Division (SISD) of Cognex Corporation (CGNX) for about $160 million. Completion of the transaction follows the receipt of all regulatory approvals.
“We are happy to declare the closing of this planned acquisition and are excited to welcome the SISD team to AMETEK,” said Frank S. Hermance, AMETEK Chairman and Chief Executive Officer. “SISD’s proprietary real-time image processing technology expands our capabilities in the non-destructive process inspection market. In addition, SISD will be able to leverage AMETEK’s complementary technology and products within its vision systems.”
AMETEK, Inc. manufactures electronic instruments and electromechanical devices worldwide. It operates in two segments, Electronic Instruments (EIG) and Electromechanical (EMG).
Shares of Depomed Inc (NASDAQ:DEPO), declined -1.05% to $31.17, during its last trading session.
Depomed, commented on Horizon Pharma plc’s (HZNP) (“Horizon”) declarement that it intends to request that Depomed’s Board of Directors (“Depomed Board”) set a record date to determine the shareholders eligible to request a special meeting.
The Depomed Board will review the request when it is received. Offered that such request is received recently and contains the information required under Depomed’s bylaws, the Depomed Board will, no later than August 31, 2015, fix a record date to determine shareholders entitled to request a special meeting, as contemplated by the bylaws. Under the bylaws, the record date to determine shareholders entitled to call a special meeting shall be not more than 60 days after the date on which the Depomed Board takes action to fix the record date. The bylaws provide that any request to call a special meeting must, among other things, be signed by the holders of shares entitled to cast not less than 10% of the votes at such meeting and must be received by Depomed within 30 days after the specified record date.
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
At the end of Monday’s trade, Shares of Becton, Dickinson and Co. (NYSE:BDX), gained 0.18% to $152.43.
Becton, Dickinson and Co., which will house research and development (R&D) and manufacturing of novel solutions for Type 1 and Type 2 diabetes.
“The opening of this facility represents an exciting opportunity for BD to accelerate the development of next-generation technologies to assist simplify the administration of Type 1 and Type 2 diabetes,” said Dr. Ellen Strahlman, chief medical officer and executive vice president of Research & Development at BD. “This new model will assist enhance the rate of innovation and enable us to provide therapeutic advances in the diabetes care sector.”
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.
Finally, Hornbeck Offshore Services, Inc. (NYSE:HOS), ended its last trade with -0.38% loss, and closed at $18.13.
Hornbeck Offshore Services, declared results for the second quarter ended June 30, 2015. Following are highlights for this period and the Company’s future outlook:
- 2Q2015 diluted EPS was $0.53, an enhance of $0.11, or 26%, from the comparable 1Q2015 diluted EPS of $0.42
- 2Q2015 EBITDA was $66.3 million, an enhance of $4.6 million, or 7%, from the comparable 1Q2015 EBITDA of $61.7 million
- 2Q2015 operating margin was 29%, up from the comparable 1Q2015 operating margin of 25%
- 2Q2015 avg new gen OSV dayrates were $28,178, up $1,500 from the sequential quarter and up $600 from the preceding-year quarter
- 2Q2015 utilization of the Company’s new gen OSV fleet was 56% contrast to 86% a year-ago and 65% sequentially
- 2Q2015 effective utilization of the Company’s active new gen OSVs was 80% contrast to 86% a year-ago and 77% sequentially
- First 17 HOSMAX vessels have been placed in-service with final seven newbuild deliveries predictable during 2H2015 and 2016
- The Company has stacked a total of 18 new generation OSVs, unchanged from its last quarterly report
- Forward line-item guidance updated to reflect actual 1H2015 results, latest market conditions and cost savings initiatives
- Cash opex and G&A savings due to proactive cost containment measures now approaching $90 million on an annualized basis
Hornbeck Offshore Services, Inc., through its auxiliaries, operates offshore supply vessels (OSVs) and multi-purpose support vessels (MPSVs) in the U.S. Gulf of Mexico, Latin America, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.